Business Context and Reporting Period
Company: Amarin Corporation plc (AMRN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Amarin is a pharmaceutical company focused on cardiovascular health, primarily commercializing VASCEPA (icosapent ethyl) in the U.S. and VAZKEPA in Europe and other regions. The company operates in a single business segment. In June 2025, Amarin executed an exclusive long-term license and supply agreement with Recordati for the commercialization of VAZKEPA in 59 European countries, triggering a Global Restructuring Plan to eliminate commercial roles in Europe and reduce annual operating costs by approximately $70 million.
Key Financial Metrics
| Metric | 2025 (in millions) | 2024 (in millions) |
|---|---|---|
| Total Revenue, Net | $213.6 | $228.6 |
| Product Revenue, Net | $182.8 | $204.6 |
| Licensing & Royalty Revenue | $30.9 | $24.0 |
| Cost of Goods Sold | $92.8 | $147.2 |
| Gross Margin | $120.9 (49%) | $81.4 (28%) |
| Operating Loss | $(50.2) | $(91.8) |
| Net Loss | $(38.8) | $(82.2) |
| Cash & Cash Equivalents | $134.7 | $121.0 |
| Short-term Investments | $167.9 | $173.2 |
| Total Liquidity | $302.6 | $294.2 |
| Debt | $0 | $0 |
Note: 2024 Cost of Goods Sold included a $36.5 million restructuring inventory charge. Excluding this charge, 2024 gross margin was 50%.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 7% to $213.6 million. U.S. product revenue fell 8% to $154.1 million due to generic competition reducing net selling prices and market share (dropping from 53% to 47%). Rest of World (RoW) product revenue declined significantly to $10.2 million from $24.2 million, reflecting variability in early-stage international markets.
- Licensing Revenue Increase: Licensing and royalty revenue increased 29% to $30.9 million, driven primarily by a $25.0 million upfront payment from the Recordati Licensing Agreement.
- Restructuring Costs: The company incurred $36.2 million in restructuring expenses in 2025 related to the Global Restructuring Plan (elimination of European commercial roles). There were no restructuring expenses in 2024.
- Improved Profitability Metrics: Despite the net loss, the operating loss narrowed significantly from $91.8 million in 2024 to $50.2 million in 2025. Gross margin improved to 49% in 2025 compared to 28% in 2024 (which was depressed by inventory restructuring charges).
- Inventory Levels: Total inventory increased to $195.9 million in 2025 from $230.8 million in 2024 (including long-term inventory), as the company aligns supply with demand.
Guidance, Outlook, and Risks
- Guidance: The company has suspended providing net revenue guidance due to the inherent nature of estimates and the impact of U.S. generic competition.
- Outlook: Management expects the Global Restructuring Plan to reduce operating costs by approximately $70 million annually. The company believes its liquidity of $302.6 million is sufficient to fund operations for at least 12 months. Future growth depends on the commercial success of VAZKEPA in Europe under the Recordati partnership and managing generic competition in the U.S.
- Key Risks:
- Generic Competition: Multiple generic versions of icosapent ethyl are active in the U.S. market, pressuring net selling prices and market share.
- Patent Litigation: A patent infringement lawsuit against Hikma regarding the REDUCE-IT indication is currently stayed pending a Supreme Court review.
- Antitrust Litigation: The company faces multiple antitrust lawsuits from generic manufacturers (Dr. Reddy's, Hikma, Teva, Apotex) alleging anticompetitive practices regarding API supply.
- Reimbursement: Commercial success in Europe and other regions is contingent on securing favorable pricing and reimbursement, which varies by country.
Investor Verification Checklist
- Recordati Partnership Execution: Verify the transition of European commercial operations to Recordati and the realization of the projected $70 million annual cost savings.
- U.S. Market Share Trends: Monitor Symphony Health prescription data to track the rate of market share erosion against generic competitors.
- Patent Litigation Status: Track the Supreme Court proceedings regarding the Hikma patent infringement case, as the outcome could impact the REDUCE-IT indication exclusivity.
- Antitrust Case Progress: Review developments in the antitrust lawsuits filed by generic manufacturers regarding API supply constraints.
- Liquidity Runway: Confirm that cash burn rates remain within projections to sustain operations without dilutive capital raises.